A venture-backed emerging biotech company needs a reliable and supportive funding source to act as a long-term financial partner during its growth. As a member of the Astellas Group, AVM can access Astellas' capital structure to work with its portfolio companies as well as with venture investors over the life of the company. Astellas understands the time and delay which emerging companies incur in seeking financing in a constantly-changing environment. While of course portfolio companies will be expected to meet performance goals and to progress in order to be financed, AVM's commitment is to build from a long-term perspective, beyond the initial investment.

This support and commitment by AVM to building a long-term relationship with the portfolio company allows the company to focus on realizing its business plans and on maximizing corporate value.

AVM expects to work in harmony with other venture investors in the company, and to be viewed by both the company and by other investors as a value-added participant in the growth of the company.